Association between Empagliflozin Use and Electrocardiographic Changes

Abstract

Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure.

Keywords

• electrocardiography
• empagliflozin
• heart failure
• SGLT2 inhibitors
• late sodium channel